<?xml version="1.0" ?><text author="Fabio Pagni, Elena Guerini-Rocco, Anne  Maria Schultheis, Giulia Grazia, Erika Rijavec, Michele Ghidini, Gianluca Lopez, Konstantinos Venetis, Giorgio  Alberto Croci, Umberto Malapelle, Nicola Fusco" dateCollected="2019-11-03" id="autogum_academic_doc014" shortTile="targeting-immunerelated" sourceURL="https://www.mdpi.com/1422-0067/20/21/5452/htm" speakerCount="0" speakerList="none" title="Targeting Immune-Related Biological Processes in Solid Tumors: We do Need Biomarkers" type="academic">
<head>
<s type="frag">
3	CD	3
.	.	.
</s>
<s type="ger">
Tailoring	VBG	Tailoring
</s>
<s type="frag">
Immunotherapy	NNP	immunotherapy
in	IN	in
Real-Life	NNP	real-life
Clinical	NNP	Clinical
Practice	NN	practice
</s>
</head>
<p>
<s type="decl">
After	IN	after
the	DT	the
histology-agnostic	JJ	histology-agnostic
approval	NN	approval
of	IN	of
pembrolizumab	NN	pembrolizumab
in	IN	in
mismatch	NN	mismatch
repair	NN	repair
(	-LRB-	(
MMR)-deficient	NNP	MMR)-deficient
tumors	NNS	tumor
,	,	,
the	DT	the
predictive	JJ	predictive
molecular	JJ	molecular
pathology	NN	pathology
scenario	NN	scenario
in	IN	in
cancer	NN	cancer
immunotherapy	NN	immunotherapy
changed	VBD	change
radically	RB	radically
.	.	.
</s>
<s type="decl">
For	IN	for
the	DT	the
first	JJ	first
time	NN	time
in	IN	in
the	DT	the
history	NN	history
of	IN	of
medicine	NN	medicine
,	,	,
a	DT	a
drug	NN	drug
(	-LRB-	(
in	IN	in
this	DT	this
case	NN	case
,	,	,
an	DT	an
immune-checkpoint	JJ	immune-checkpoint
inhibitor	NN	inhibitor
)	-RRB-	)
was	VBD	be
approved	VBN	approve
based	VBN	base
on	IN	on
a	DT	a
specific	JJ	specific
molecular	JJ	molecular
feature	NN	feature
of	IN	of
the	DT	the
neoplasm	NN	neoplasm
,	,	,
irrespective	NN	irrespective
of	IN	of
its	PRP$	its
anatomical	JJ	anatomical
site	NN	site
of	IN	of
origin	NN	origin
.	.	.
</s>
<s type="decl">
A	DT	a
multitude	NN	multitude
of	IN	of
different	JJ	different
tools	NNS	tool
has	VBZ	have
been	VBN	be
proposed	VBN	propose
to	TO	to
inform	VB	inform
immunotherapy	NN	immunotherapy
,	,	,
including	VBG	include
morphology	NN	morphology
,	,	,
immunohistochemistry	NN	immunohistochemistry
(	-LRB-	(
IHC	NNP	IHC
)	-RRB-	)
,	,	,
polymerase	NN	polymerase
chain	NN	chain
reaction	NN	reaction
(	-LRB-	(
PCR)-based	JJ	PCR)-based
techniques	NNS	technique
and	CC	and
next-generation	NN	next-generation
technology	NN	technology
assays	NNS	assays
,	,	,
such	JJ	such
as	IN	as
next-generation	NN	next-generation
sequencing	NN	sequence
(	-LRB-	(
NGS	NNP	NGS
)	-RRB-	)
or	CC	or
multiplex	NN	multiplex
barcode	NN	barcode
technology	NN	technology
(	-LRB-	(
e.	NNP	e.
g.	NNP	g.
,	,	,
NanoString	NNP	nanoString
)	-RRB-	)
.	.	.
</s>
<s type="decl">
However	RB	however
,	,	,
not	RB	not
all	PDT	all
the	DT	the
available	JJ	available
tools	NNS	tool
are	VBP	be
validated	VBN	validate
for	IN	for
patients	NNS	patient
’	POS	's
selection	NN	selection
in	IN	in
clinical	JJ	clinical
practice	NN	practice
,	,	,
as	IN	as
shown	VBN	show
in	IN	in
<figure>
Figure	NNP	Figure
1	CD	1
</figure>
.	.	.
</s>
</p>
<p>
<s type="decl">
Among	IN	Among
new	JJ	new
biomarkers	NNS	biomarker
to	TO	to
select	VB	select
patients	NNS	patient
for	IN	for
immunotherapy	NN	immunotherapy
,	,	,
the	DT	the
tumor	NN	tumor
mutational	JJ	mutational
burden	NN	burden
(	-LRB-	(
TMB	NNP	TMB
)	-RRB-	)
has	VBZ	have
been	VBN	be
shown	VBN	show
a	DT	a
strong	JJ	strong
correlation	NN	correlation
with	IN	with
the	DT	the
response	NN	response
to	TO	to
some	DT	some
compounds	NNS	compound
.	.	.
</s>
<s type="decl">
TMB	NNP	TMB
is	VBZ	be
defined	VBN	define
by	IN	by
the	DT	the
total	JJ	total
number	NN	number
of	IN	of
somatic	JJ	somatic
nonsynonymous	NN	nonsynonymous
mutations	NNS	mutation
per	IN	per
coding	NN	coding
area	NN	area
of	IN	of
the	DT	the
tumor	NN	tumor
DNA	NNP	NN
.	.	.
</s>
<s type="decl">
It	PRP	it
has	VBZ	have
been	VBN	be
hypothesized	VBN	hypothesize
that	IN	that
tumors	NNS	tumor
with	IN	with
a	DT	a
higher	JJR	high
TMB	NNP	TMB
are	VBP	be
more	RBR	more
likely	JJ	likely
to	TO	to
express	VB	express
neoantigens	NNS	neoantigen
and	CC	and
to	TO	to
induce	VB	induce
a	DT	a
more	RBR	more
robust	JJ	robust
immune	JJ	immune
response	NN	response
in	IN	in
the	DT	the
presence	NN	presence
of	IN	of
immune	NN	immune
checkpoint	NN	checkpoint
inhibitors	NNS	inhibitor
.	.	.
</s>
<s type="decl">
Regrettably	RB	regrettably
,	,	,
the	DT	the
TMB	NNP	TMB
analysis	NN	analysis
is	VBZ	be
considered	VBN	consider
expensive	JJ	expensive
,	,	,
time-consuming	VBG	time-consuming
,	,	,
and	CC	and
deceptive	JJ	deceptive
if	IN	if
the	DT	the
analyses	NNS	analysis
are	VBP	be
carried	VBN	carry
out	RP	out
with	IN	with
an	DT	an
unsuitable	JJ	unsuitable
NGS	NNP	NGS
panel	NN	panel
.	.	.
</s>
<s type="decl">
Another	DT	another
important	JJ	important
facet	NN	facet
in	IN	in
TMB	NNP	TMB
analysis	NN	analysis
is	VBZ	be
represented	VBN	represent
by	IN	by
the	DT	the
lack	NN	lack
of	IN	of
widely	RB	widely
adopted	VBN	adopt
guidelines	NNS	guideline
and	CC	and
recommendations	NNS	recommendation
for	IN	for
its	PRP$	its
assessment	NN	assessment
and	CC	and
reporting	NN	report
.	.	.
</s>
<s type="decl">
Initially	RB	initially
,	,	,
TMB	NNP	TMB
was	VBD	be
determined	VBN	determine
using	VBG	use
wide	JJ	wide
approaches	NNS	approach
(	-LRB-	(
e.	NNP	e.
g.	FW	g.
,	,	,
whole	JJ	whole
exome	NN	exome
sequencing	NN	sequence
)	-RRB-	)
,	,	,
but	CC	but
more	RBR	more
focused	VBN	focus
gene	NN	gene
panels	NNS	panel
are	VBP	be
currently	RB	currently
being	VBG	be
explored	VBN	explore
.	.	.
</s>
<s type="decl">
In	IN	in
addition	NN	addition
,	,	,
there	EX	there
are	VBP	be
several	JJ	several
indications	NNS	indication
that	WDT	that
TMB	NNP	TMB
is	VBZ	be
not	RB	not
a	DT	a
universal	JJ	universal
biomarker	NN	biomarker
,	,	,
as	IN	as
its	PRP$	its
value	NN	value
varies	VBZ	vary
not	RB	not
only	RB	only
across	IN	across
tumor	NN	tumor
types	NNS	type
but	CC	but
also	RB	also
across	IN	across
different	JJ	different
genomic	JJ	genomic
regions	NNS	region
and	CC	and
during	IN	during
the	DT	the
time	NN	time
.	.	.
</s>
<s type="decl">
This	DT	this
notion	NN	notion
highlights	VBZ	highlight
the	DT	the
need	NN	need
for	IN	for
disease-specific	JJ	disease-specific
TMB	NNP	TMB
panels	NNS	panel
and	CC	and
thresholds	NNS	threshold
.	.	.
</s>
</p>
<p>
<s type="decl">
Likewise	RB	likewise
,	,	,
the	DT	the
analysis	NN	analysis
of	IN	of
the	DT	the
MMR	NNP	MMR
status	NN	status
is	VBZ	be
troubled	VBN	troubled
by	IN	by
the	DT	the
vastity	NN	vastity
of	IN	of
the	DT	the
existing	VBG	exist
diagnostic	JJ	diagnostic
methods	NNS	method
in	IN	in
the	DT	the
substantial	JJ	substantial
absence	NN	absence
of	IN	of
companion	NN	companion
diagnostic	NN	diagnostic
(	-LRB-	(
CD	NN	CD
)	-RRB-	)
tests	NNS	test
.	.	.
</s>
<s type="decl">
In	IN	in
general	NN	general
,	,	,
MMR	NNP	MMR
IHC	NNP	IHC
is	VBZ	be
mirrored	VBN	mirrore
by	IN	by
microsatellite	JJ	microsatellite
instability	NN	instability
(	-LRB-	(
MSI	NNP	MSI
)	-RRB-	)
in	IN	in
endometrial	NN	endometrial
and	CC	and
colorectal	JJ	colorectal
cancers	NNS	cancer
.	.	.
</s>
<s type="decl">
However	RB	however
,	,	,
not	RB	not
all	DT	all
MMR-deficient	NNP	MMR-deficient
tumors	NNS	tumor
show	VBP	show
MSI	NNP	MSI
(	-LRB-	(
e.	NNP	e.
g.	NNP	g.
,	,	,
breast	NN	breast
cancers	NNS	cancer
)	-RRB-	)
,	,	,
questioning	VBG	question
the	DT	the
interchangeability	NN	interchangeability
of	IN	of
these	DT	these
analyses	NNS	analysis
as	IN	as
pan-cancer	JJ	pan-cancer
predictive	JJ	predictive
tests	NNS	test
.	.	.
</s>
<s type="decl">
Hence	RB	hence
,	,	,
MMR/MSI	NNP	MMR/MSI
assays	NNS	assays
have	VBP	have
been	VBN	be
originally	RB	originally
developed	VBN	develop
by	IN	by
geneticists	NNS	geneticist
to	TO	to
identify	VB	identify
Lynch	NNP	lynch
syndrome	NN	syndrome
families	NNS	family
and	CC	and
not	RB	not
for	IN	for
choosing	VBG	choose
the	DT	the
optimal	JJ	optimal
drug	NN	drug
to	TO	to
treat	VB	treat
acquired	VBN	acquire
tumors	NNS	tumor
.	.	.
</s>
<s type="decl">
Given	VBN	give
the	DT	the
wide	JJ	wide
heterogeneity	NN	heterogeneity
in	IN	in
the	DT	the
repertoire	NN	repertoire
of	IN	of
molecular	JJ	molecular
alterations	NNS	alteration
in	IN	in
immune-related	VBN	immune-related
genes	NNS	gene
across	IN	across
different	JJ	different
tumor	NN	tumor
types	NNS	type
(	-LRB-	(
<figure>
Figure	NN	Figure
2	CD	2
</figure>
)	-RRB-	)
,	,	,
novel	NN	novel
,	,	,
efficient	JJ	efficient
,	,	,
reproducible	JJ	reproducible
,	,	,
and	CC	and
reliable	JJ	reliable
techniques	NNS	technique
coupled	VBN	coupled
with	IN	with
tumor-specific	JJ	tumor-specific
methods	NNS	method
and	CC	and
guidelines	NNS	guideline
are	VBP	be
needed	VBN	need
.	.	.
</s>
</p>
<p>
<s type="decl">
Another	DT	another
important	JJ	important
issue	NN	issue
related	VBN	relate
to	TO	to
the	DT	the
patient	NN	patient
’s	POS	's
selection	NN	selection
for	IN	for
immunotherapy	NN	immunotherapy
is	VBZ	be
represented	VBN	represent
by	IN	by
the	DT	the
PD-L1	NNP	PD-L1
analysis	NN	analysis
by	IN	by
IHC	NNP	IHC
.	.	.
</s>
<s type="decl">
In	IN	in
this	DT	this
respect	NN	respect
,	,	,
important	JJ	important
harmonization	NN	harmonization
efforts	NNS	effort
have	VBP	have
been	VBN	be
made	VBN	make
to	TO	to
standardize	VB	standardize
both	CC	both
the	DT	the
preanalytical	JJ	preanalytical
and	CC	and
interpretative	JJ	interpretative
phases	NNS	phase
of	IN	of
PD-L1	NNP	PD-L1
testing	NN	testing
,	,	,
at	IN	at
least	JJS	least
in	IN	in
non-small	JJ	non-small
cell	NN	cell
lung	NN	lung
cancer	NN	cancer
(	-LRB-	(
NSCLC	NNP	NSCLC
)	-RRB-	)
.	.	.
</s>
<s type="decl">
The	DT	the
reproducibility	NN	reproducibility
of	IN	of
PD-L1	NNP	PD-L1
testing	NN	testing
in	IN	in
real-life	JJ	real-life
clinical	JJ	clinical
practice	NN	practice
evaluated	VBN	evaluate
both	DT	both
for	IN	for
“	``	"
closed	VBN	close
”	''	"
and	CC	and
“	``	"
open	JJ	open
”	''	"
platforms	NNS	platform
,	,	,
showed	VBD	show
overlapping	VBG	overlapp
results	NNS	result
,	,	,
particularly	RB	particularly
when	WRB	when
the	DT	the
22C3	CD	@card@
antibody	NN	antibody
clone	NN	clone
was	VBD	be
used	VBN	use
.	.	.
</s>
<s type="decl">
On	IN	on
the	DT	the
other	JJ	other
hand	NN	hand
,	,	,
there	EX	there
are	VBP	be
several	JJ	several
clues	NNS	clue
to	TO	to
advise	VB	advise
that	IN	that
the	DT	the
same	JJ	same
interpretation	NN	interpretation
guidelines	NNS	guideline
should	MD	should
not	RB	not
be	VB	be
translated	VBN	translate
across	IN	across
different	JJ	different
tumor	NN	tumor
types	NNS	type
.	.	.
</s>
<s type="decl">
For	IN	for
example	NN	example
,	,	,
the	DT	the
tumor	NN	tumor
proportion	NN	proportion
score	NN	score
(	-LRB-	(
TPS	NNP	TPS
)	-RRB-	)
works	VBZ	work
perfectly	RB	perfectly
for	IN	for
lung	NN	lung
cancer	NN	cancer
but	CC	but
not	RB	not
for	IN	for
head	NN	head
and	CC	and
neck	NN	neck
cancer	NN	cancer
,	,	,
where	WRB	where
the	DT	the
combined	JJ	combine
positive	JJ	positive
score	NN	score
(	-LRB-	(
CPS	NNP	CPS
)	-RRB-	)
is	VBZ	be
more	RBR	more
reliable	JJ	reliable
.	.	.
</s>
<s type="decl">
These	DT	these
two	CD	two
scoring	VBG	score
systems	NNS	system
are	VBP	be
rather	RB	rather
different	JJ	different
,	,	,
given	VBN	give
that	IN	that
the	DT	the
former	JJ	former
considers	VBZ	consider
only	RB	only
the	DT	the
percentage	NN	percentage
of	IN	of
PD-L1-positive	JJ	PD-L1-positive
neoplastic	JJ	neoplastic
cells	NNS	cell
,	,	,
while	IN	while
the	DT	the
latter	JJR	latter
combines	VBZ	combine
all	DT	all
PD-L1-positive	JJ	PD-L1-positive
cells	NNS	cell
(	-LRB-	(
i.	FW	i.
e.	FW	e.
,	,	,
tumor	NN	tumor
cells	NNS	cell
,	,	,
lymphocytes	NNS	lymphocyte
,	,	,
and	CC	and
macrophages	NNS	macrophage
)	-RRB-	)
into	IN	into
the	DT	the
following	VBG	follow
formula	NN	formula
.	.	.
</s>
</p>
<p>
<s type="decl">
Although	IN	although
the	DT	the
CPS	NNP	CPS
can	MD	can
theoretically	RB	theoretically
exceed	VB	exceed
the	DT	the
value	NN	value
of	IN	of
100	CD	@card@
,	,	,
the	DT	the
maximum	JJ	maximum
score	NN	score
is	VBZ	be
defined	VBN	define
as	IN	as
100	CD	@card@
.	.	.
</s>
<s type="decl">
Fascinating	VBG	fascinate
perspectives	NNS	perspective
are	VBP	be
being	VBG	be
provided	VBN	provide
by	IN	by
experimental	JJ	experimental
models	NNS	model
addressing	VBG	address
the	DT	the
plasticity	NN	plasticity
of	IN	of
the	DT	the
cellular	JJ	cellular
inflammatory	JJ	inflammatory
response	NN	response
of	IN	of
the	DT	the
host	NN	host
.	.	.
</s>
<s type="decl">
There	EX	There
are	VBP	be
several	JJ	several
lines	NNS	line
of	IN	of
evidence	NN	evidence
to	TO	to
suggest	VB	suggest
that	IN	that
the	DT	the
myeloid-derived	JJ	myeloid-derived
cell	NN	cell
function	NN	function
is	VBZ	be
a	DT	a
finely	RB	finely
tuned	VBN	tune
mechanism	NN	mechanism
to	TO	to
control	VB	control
tumor	NN	tumor
growth	NN	growth
.	.	.
</s>
<s type="decl">
Specifically	RB	specifically
,	,	,
both	DT	both
in	IN	in
local	JJ	local
and	CC	and
hematopoietic	JJ	hematopoietic
niches	NNS	nich
,	,	,
its	PRP$	its
crosstalk	NN	crosstalk
with	IN	with
the	DT	the
tumor	NN	tumor
cells	NNS	cell
as	RB	as
well	RB	well
as	IN	as
with	IN	with
exogenous	JJ	exogenous
stimuli	NNS	stimulus
,	,	,
is	VBZ	be
based	VBN	base
on	IN	on
the	DT	the
microbiota	NN	microbiota
repertoire	NN	repertoire
.	.	.
</s>
</p>
</text>